Cyclin B1 and other cyclins as tumor antigens in immunosurveillance and immunotherapy of cancer

Cancer Research

Volumn 66, Issue 1, 2006, Pages 6-9

  Egloff, Ann Marie ^a   Vella, Laura A ^a   Finn, Olivera J ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLIN E; CYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MUCIN 1; PROTEIN P53;

ANTIBODY RESPONSE; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; BREAST ADENOCARCINOMA; CANCER DIAGNOSIS; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE S PHASE; CELL DIVISION; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; EARLY DIAGNOSIS; GENE FUNCTION; GENE INACTIVATION; GENE OVEREXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOSURVEILLANCE; LIVER CELL CARCINOMA; LUNG CANCER; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN TARGETING; REVIEW; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGENS, NEOPLASM; CYCLIN B; HUMANS; IMMUNOTHERAPY; MONITORING, IMMUNOLOGIC; NEOPLASMS;

EID: 31544472829     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3389     Document Type: Review

References (20)

1. Graziano DF, Finn OJ. Tumor antigens and tumor antigen discovery. In: Kheif S, editor. Tumor immunology and cancer vaccines. New York: Klewer Acad. Publ.; 2004. p. 89-111.
2. Egloff AM, Weissfeld J, Land SR, Finn OJ. Evaluation of anti-cyclin B1 antibodies as a diagnostic and prognostic biomarker for lung cancer. Ann N Y Acad Sci 2005;1062:29-40.
3. Singhal S. Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM. Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review. Clin Cancer Res 2005;11:3974-86.
4. Covini G, Chan EK, Nishioka M, Morshed SA, Reed SI, Tan EM. Immune response to cyclin B1 in hepatocellular carcinoma. Hepatology 1997;25:75-80.
5. Kao H, Marto JA, Hoffmann TK, et al. Identification of cyclin B1 as a shared human epithelial tumor-associated antigen recognized by T cells. J Exp Med 2001;194:1313-23.
6. Koziol JA, Zhang JY, Casiano CA, et al. Recursive partitioning as an approach to selection of immune markers for tumor diagnosis. Clin Cancer Res 2003;9:5120-6.
7. Suzuki H, Graziano DF, McKolanis J, Finn OJ. T cell-dependent antibody responses against aberrantly expressed cyclin Bl protein in patients with cancer and premalignant disease. Clin Cancer Res 2005;11:1521-6.
8. Porter LA, Donoghue DJ. Cyclin B1 and CDK1: nuclear localization and upstream regulators. Prog Cell Cycle Res 2003;5:335-47.
9. Yu M, Zhan Q, Finn OJ. Immune recognition of cyclin B1 as a tumor antigen is a result of its overexpression in human tumors that is caused by non-functional p53. Mol Immunol 2002;38:981-7.
10. Vlad AM, Kettel JC, Alajez NM, Carlos CA. Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004;82:249-93.
11. Kiessling R, Wei WZ, Herrmann F, et al. Cellular immunity to the Her-2/neu protooncogene. Adv Cancer Res 2002;85:101-44.
12. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF, Carbone DP. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 1992;52:4168-74.
13. Betticher DC, Heighway J, Hasleton PS, et al. Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer 1996;73:294-300.
14. Shi FD, Zhang JY, Liu D, et al. Preferential humoral immune response in prostate cancer to cellular proteins p90 and p62 in a panel of tumor-associated antigens. Prostate 2005;63:252-8.
15. Yasmeen A, Berdel WE, Serve H, Muller-Tidow C. E- and A-type cyclins as markers for cancer diagnosis and prognosis. Expert Rev Mol Diagn 2003;3:617-33.
16. Hwang HC, Clurman BE, Cyclin E in normal and neoplastic cell cycles. Oncogene 2005;24:2776-86.
17. Harwell RM, Porter DC, Danes C, Keyomarsi K. Processing of cyclin E differs between normal and tumor breast cells. Cancer Res 2000;60:481-9.
18. Juan G, Cordon-Cardo C. Intranuclear compartmentalization of cyclin E during the cell cycle: disruption of the nucleoplasm-nucleolar shuttling of cyclin E in bladder cancer. Cancer Res 2001;61:1220-6.
19. Ekberg J, Holm C, Jalili S, et al. Expression of cyclin Al and cell cycle proteins in hematopoietic cells and acute myeloid leukemia and links to patient outcome. Eur J Haematol 2005;75:106-15.
20. Ekberg J, Landberg G, Holm C, Richter J, Wolgemuth DJ, Persson JL. Regulation of the cyclin A1 protein is associated with its differential subcellular localization in hematopoietic and leukemic cells. Oncogene 2004;23:9082-9.